Freya Meds vs RestorLife Med
Two GLP-1 desks, one scoreboard. We put Freya Meds and RestorLife Med head-to-head on the published Brief Score — the same six factors, scored the same way.
RestorLife Med
The verdict
RestorLife Med takes this head-to-head.
RestorLife Med scores 85 to 67 on our six-factor Brief Score — A LegitScript-certified, nationwide desk that trades a premium sticker for accreditation and clean disclosure.
That doesn't make Freya Meds a bad call — it's best for patients wanting dietitian-supported compounded glp-1 programs. Weigh the six factors below against your own priorities before you decide.
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Brief Score.
Factor by factor
Both desks scored on the six published Brief Score factors. The higher score in each row is marked. See the methodology.
Price, coverage & the tracker
| Freya Meds | RestorLife Med | |
|---|---|---|
| Brief Score | 67/100 (C) | 85/100 (B) |
| Semaglutide | From $297/mo (compounded) | $299/mo |
| Tirzepatide | From $390/mo (compounded) | $399/mo |
| Coverage | Coverage not published | All 50 states |
| Brand-name access | Compounded only | Compounded only |
| Oral / sublingual | Injection only | Injection only |
| On the tracker | Newnew to the tracker, no prior reading | Stableprice stable |
Freya Meds: New to the tracker on 1 August 2026. The published line reads From $297/mo (compounded) at our first reading; there is no earlier reading of ours to compare it against yet.
RestorLife Med: $299 sema / $399 tirz nationwide; LegitScript-certified.
● Not sold on either?
CoreAge Rx tops the whole ranking at 94/100.
The steadiest desk in the ranking: one flat, no-step-up price on both molecules, nationwide, and it hasn't moved.
Pricing, states and access reflect each provider's public disclosures at last review; the Brief Score is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.